EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.
- In addition, further market launches are planned in Algeria and other Gulf Cooperation Council (GCC) markets over the course of 2024.
- This strategic collaboration aims to improve access to ophthalmic treatments in the MENA region.
- Biosimilar and specialty medicines are integral to MS Pharma product portfolio and play a crucial role in advancing our growth objectives in the MENA region.
- This approval supports the company's commitment to the Saudi market and its broader strategic initiatives within the kingdom."